Keywords: Astellas, Mirabegron, OAB, Overactive bladder, Betanis, USA, Europe
Astellas files for OAB drug mirabegron in USA and Europe
Article | 01 September 2011
Japanese drug major Astellas Pharma (TYO: 4503) says it has submitted a New Drug Application and Market Authorisation Application for mirabegron ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
